MedTrace Logo

Treatment of Low-flow Venous Malformations With Electrosclerotherapy. Prospective Observational Study

NCT06189092 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2026-05-22

No results posted yet for this study

Summary

Venous malformations (MVs) are congenital abnormalities of the central or periphery caused by developmental errors at different stages of embryogenesis. Histologically they are characterized by large, venous-like vascular spaces. Scleroembolization constitutes the most widespread method in the treatment of venous malformations allowing good results with low invasiveness. Currently, Bleomycin (and its derivatives) is among the most widely used sclerosing agents for slow-flowing vascular malformations (venous and lymphatic malformations) because of the low rate of local serious adverse events such as swelling, necrosis, and nerve injury compared with others.

Conditions

  • Vascular Malformations

Interventions

DRUG

Bleomycin

Using electroporation to infuse bleomycin in the lesion

Sponsors & Collaborators

  • Istituto Ortopedico Rizzoli

    lead OTHER

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-28
Primary Completion
2026-11-28
Completion
2027-11-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06189092 on ClinicalTrials.gov